SOPHiA DDM HRD Solution combines information from germline and somatic HRR mutations with a measure of genomic scarring. Accelerate and empower your clinical cancer research decisions with cost-effective, reliable, and timely in-house results.
Hiroshima University to Utilize Myeloid Plus Solution
Hiroshima University aimed to establish a framework where the NGS-based testing would become a routine part of clinical diagnosis for myeloid neoplasms.
Advanced customizable RNA-based sequencing approach that offers a single convenient workflow with confident novel fusion detection, while also providing ability to detect SNV/Indels and expression changes.
The information included in this document has been prepared for and is intended for viewing by a global audience. This document contains information about products and services which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indication for use. Please consult local sales representative.
